Health insurance company Cigna (NYSE:CI) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.4% year on year to $65.5 billion. Its non-GAAP profit of $6.74 per share was 6.2% above analysts’ consensus estimates.
Revenue: $65.5 billion vs analyst estimates of $60.42 billion (14.4% year-on-year growth, 8.4% beat)
Adjusted EPS: $6.74 vs analyst estimates of $6.35 (6.2% beat)
Adjusted EBITDA: $2.81 billion vs analyst estimates of $2.86 billion (4.3% margin, 1.7% miss)
Operating Margin: 3%, in line with the same quarter last year
Free Cash Flow Margin: 2.4%, down from 7.9% in the same quarter last year
Customers: 16.36 million, down from 17.5 million in the previous quarter
Market Capitalization: $82.51 billion
StockStory’s Take
Cigna’s Q1 results were shaped by continued momentum in its core health services and integrated benefits businesses, with leadership attributing growth to double-digit expansion in specialty pharmacy, strong pharmacy benefit services performance, and notable customer gains in the under-500 employer segment. CEO David Cordani highlighted the company’s dual-platform model—EverNorth and Cigna Healthcare—as key to capturing new opportunities in a rapidly evolving healthcare landscape. New CFO Ann Dennison and President Brian Evanko, both recently appointed, also played prominent roles in outlining operational progress and financial discipline.
Looking ahead, management’s guidance is underpinned by expectations for sustained demand in specialty drugs, increased biosimilar adoption, and continued investments in digital tools and clinical programs. Cordani stated, "We are confident in our ability to sustainably deliver 10% to 14% compounded EPS growth over the strategic horizon," while Evanko emphasized new product launches and service enhancements, particularly around GLP-1 treatments, as important contributors to future growth.
Key Insights from Management’s Remarks
Cigna’s management discussed several operational and strategic themes that influenced Q1 performance, with an emphasis on leveraging its platform strengths and responding to industry shifts. The quarter’s results were largely attributed to product innovation, customer growth in targeted segments, and disciplined capital deployment.
Specialty Pharmacy Expansion: Management pointed to double-digit growth in EverNorth’s specialty and care services, driven by rising demand for clinically intensive medications and expanded biosimilar offerings, such as the new Humira and Stelara alternatives.
GLP-1 Clinical Solutions: The company introduced new programs (EncircleRx, inReachRx, and InGuide) aimed at supporting GLP-1 medication access and affordability, addressing both employer cost concerns and patient adherence challenges.
Customer Growth in Select Segment: Cigna Healthcare’s under-500 employer group saw 9% year-over-year customer growth, attributed to flexible funding models and consultative client engagement, with management noting significant market share headroom.
Medicare Business Divestiture: The completion of the Medicare business sale modestly benefited Q1 earnings and reflects Cigna’s ongoing portfolio optimization, enabling a greater focus on core growth platforms.
Capital Management Discipline: The company reaffirmed its capital allocation priorities: supporting business growth, pursuing bolt-on acquisitions, and returning excess capital to shareholders through repurchases and dividends. No major capability gaps were identified for near-term M&A focus.
Drivers of Future Performance
Management’s outlook for the next quarter and full year centers on specialty drug growth, biosimilar adoption, and continued operational investments, while acknowledging ongoing industry cost pressures and regulatory change.
Specialty Drug and Biosimilar Uptake: Management believes that expanding use of specialty medications and biosimilars, particularly GLP-1s and new interchangeable drugs, will underpin revenue and margin growth in both EverNorth and Cigna Healthcare.
Digital and Clinical Program Investments: Ongoing rollout of digital tools and personalized clinical programs is expected to enhance patient experience, support client retention, and drive differentiation in the pharmacy benefits market.
Regulatory and Cost Trend Risks: The company cited persistent medical cost trends, evolving drug pricing dynamics, and regulatory changes (e.g., state-level PBM legislation) as key variables that could affect future performance, with planning assumptions remaining prudent.
Top Analyst Questions
Lisa Gill (JP Morgan): Asked about Cigna’s strategy for negotiating better GLP-1 pricing and employer coverage trends. Management highlighted competition among manufacturers and comprehensive solution design, noting stable coverage rates and the potential for greater employer adoption as prices decline.
A.J. Rice (UBS): Inquired about demand drivers in the pharmacy benefit selling season and employer focus areas. Management cited affordability, specialty drug growth, and personalized clinical programs as current priorities, with strong retention in Express Scripts and customer gains in the select segment.
Justin Lake (Wolfe Research): Requested detail on stop-loss margin recovery and client feedback. Management reiterated that the margin improvement plan is on track, with revised pricing incorporated into renewals and retention levels holding steady.
Charles Rhyee (TD Cowen): Asked about the impact of Arkansas legislation targeting PBM-pharmacy integration. Management opposed the bill, emphasizing the value of integrated capabilities for savings and access, and advocated for enhanced transparency and client choice instead of regulatory restrictions.
Ann Hynes (Mizuho Securities): Queried Cigna’s capital deployment and M&A priorities. Leadership reaffirmed a focus on supporting core growth, disciplined bolt-on acquisitions, and no immediate need for new capabilities in either health insurance or EverNorth.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) the pace of specialty drug and biosimilar adoption, especially in GLP-1 and Stelara categories, (2) the effectiveness of new digital and clinical support tools in driving client retention and patient satisfaction, and (3) the company’s execution on stop-loss margin improvement plans. Additional attention will be paid to regulatory developments affecting pharmacy benefit management and the competitive response to Cigna’s evolving product portfolio.
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
